Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
KRRO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
8 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Quote Panel
Key Metrics
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-15.50
vs -3.74
Q4.23
N/A
-25.65
vs -3.21
Q1.24
N/A
-2.44
vs -0.55
Q2.24
N/A
-2.43
vs -0.30
Q3.24
N/A
-2.26
vs -15.50
Q4.24
N/A
-2.26
vs -25.65
Q1.25
N/A
-2.49
vs -2.44
Q2.25
N/A
-2.74
vs -2.43
Q3.25
N/A
-2.57
vs -2.26
Q4.25
N/A
-2.48
vs -2.26
Sales Growth
YoY
Current
Estimates
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
2.3M vs NA
Q1.25
NA
2.5M vs NA
Q2.25
NA
1.5M vs NA
Q3.25
NA
463K vs NA
Q4.25
-76%
545.5K vs 2.3M
Return on Equity
QoQ
Q1.23
-37%
-0.37
vs -0.25
Q2.23
+8%
0.08
vs -0.37
Q3.23
-32%
-0.32
vs 0.08
Q4.23
-23%
-0.23
vs -0.32
Q1.24
-13%
-0.13
vs -0.23
Q2.24
-11%
-0.11
vs -0.13
Q3.24
-12%
-0.12
vs -0.11
Q4.24
-13%
-0.13
vs -0.12
Q1.25
-17%
-0.17
vs -0.13
Q2.25
-22%
-0.22
vs -0.17
Institutionnal Ownership
QoQ
Q4.22
NA
NA
vs NA
NA
Q1.23
NA
NA
vs NA
NA
Q2.23
NA
NA
vs NA
NA
Q3.23
NA
NA
vs NA
NA
Q4.23
40
40
vs NA
NA
Q1.24
49
49
vs 40
23%
Q2.24
63
63
vs 49
29%
Q3.24
70
70
vs 63
11%
Q4.24
82
82
vs 70
17%
Q1.25
71
71
vs 82
-13%
Forecast
78%2026-Revenue
-256%2026-EPS
99%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
Cantor Fitzgerald
initialisePrevious: Not converted
2025-04-28
Now: Overweight
Oppenheimer
initialisePrevious: Not converted
2025-01-10
Now: Outperform
Raymond James
initialisePrevious: Not converted
2024-10-21
Now: Strong Buy
William Blair
initialisePrevious: Not converted
2024-08-14
Now: Outperform
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
-0.54Â ( -2.67%)
Relative Strenght
54
Volume Buzz
5%
Earning Acce
No
Dist 52w H.
80%Relative Strength
KRRO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How KRRO compares to sector?
KRRO
-2x